Text Size

Study of Ivacaftor in Cystic Fibrosis Subjects Aged 12 Years and Older Homozygous for the F508del-CFTR Mutation (DISCOVER)

This study is ongoing, but not recruiting participants.
Sponsor:
Collaborator:
Cystic Fibrosis Foundation
Information provided by (Responsible Party):
Vertex Pharmaceuticals Incorporated
ClinicalTrials.gov Identifier:
NCT00953706
First received: August 4, 2009
Last updated: October 25, 2012
Last verified: October 2012
History of Changes
  Purpose

The purpose of this study was to evaluate the safety and efficacy of ivacaftor in patients with cystic fibrosis who were aged 12 years or older and were homozygous for the F508del-CFTR mutation. Ivacaftor is a potent and selective cystic fibrosis transmembrane conductance regulator (CFTR) potentiator of wild-type, G551D, F508del, and R117H forms of human CFTR protein. Potentiators are pharmacological agents that increase the chloride ion transport properties of the channel in the presence of cyclic adenosine monophosphate (AMP)-dependent protein kinase A (PKA) activation.


Condition Intervention Phase
Cystic Fibrosis
 Drug: Ivacaftor
Drug: Placebo
 Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Safety and Efficacy of VX-770 in Subjects Aged 12 Years and Older With Cystic Fibrosis Who Are Homozygous for the F508del-CFTR Mutation

Resource links provided by NLM:

Drug Information available for: Ivacaftor
U.S. FDA Resources

Further study details as provided by Vertex Pharmaceuticals Incorporated:

Primary Outcome Measures:
  • Absolute Change From Baseline in Percent Predicted Forced Expiratory Volume in 1 Second (FEV1) Through Week 16 [ Time Frame: baseline through 16 weeks ] [ Designated as safety issue: No ]
    Spirometry (as measured by FEV1) is a standardized assessment to evaluate lung function that is the most widely used endpoint in cystic fibrosis studies.


Secondary Outcome Measures:
  • Absolute Change From Baseline in Cystic Fibrosis Questionnaire-Revised (CFQ-R) Score Through Week 16 (Respiratory Domain Score, Pooled) [ Time Frame: baseline through 16 weeks ] [ Designated as safety issue: No ]
    The CFQ-R is a health-related quality of life measure for subjects with cystic fibrosis. Each domain is scored from 0 (worst) to 100 (best). A difference of at least 4 points in the respiratory domain score of the CFQ-R is considered a minimal clinically important difference (MCID).

  • Absolute Change From Baseline in Sweat Chloride Concentration Through Week 16 [ Time Frame: baseline through 16 weeks ] [ Designated as safety issue: No ]
    The sweat chloride (quantitative pilocarpine iontophoresis) test is a standard diagnostic tool for cystic fibrosis (CF), serving as an indicator of cystic fibrosis transmembrane conductance regulator (CFTR) activity.

  • Rate of Change From Baseline in Weight Through Week 16 [ Time Frame: baseline to 16 weeks ] [ Designated as safety issue: No ]
    As malnutrition is common in patients with cystic fibrosis (CF) because of increased energy expenditures due to lung disease and fat malabsorption, body weight is an important clinical measure of nutritional status.


Enrollment: 140
Study Start Date: September 2009
Estimated Study Completion Date: June 2013
Primary Completion Date: July 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Placebo Comparator: Placebo
Subjects in Part A who received placebo every 12 hours (q12h) for 16 weeks.
 Drug: Placebo
Tablets given orally q12h for 16 weeks
Experimental: 150 mg Ivacaftor q12h
Subjects in Part A who received 150 mg of ivacaftor q12h for 16 weeks.
 Drug: Ivacaftor
150-mg tablets given orally q12h for 16 weeks
Other Name: VX-770

Detailed Description:

This study investigated the effects of ivacaftor in subjects with cystic fibrosis (CF) ≥ 12 years of age with an forced expiratory volume in 1 second (FEV1) ≥ 40% predicted. This study was conducted in 2 parts. This posting describes Part A only.

  • Part A of this study was a randomized, double-blind, placebo-controlled, parallel-group evaluation of subjects with CF who were aged 12 years or older and were homozygous for the F508del-CFTR mutation. At 34 centers in the US, 140 subjects were enrolled and randomized to receive either 150 mg ivacaftor q12h (112 subjects) or placebo (28 subjects) for 16 weeks.
  • Part B of this study was an open-label extension of Part A, enrolling subjects who completed Part A, and explored the safety and efficacy of ivacaftor over long-term treatment in subjects with CF aged 12 years or older who were homozygous for the F508del-CFTR mutation.
  Eligibility

Ages Eligible for Study:   12 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Confirmed diagnosis of cystic fibrosis (CF) and homozygous for F508del-CFTR mutation
  • Forced expiratory volume in 1 second (FEV1) of at least 40% of predicted normal for age, gender, and height
  • Willing to use at least 2 highly effective birth control methods during the study
  • No clinically significant abnormalities that would have interfered with the study assessments, as judged by the investigator
  • Able to understand and comply with protocol requirements, restrictions, and instructions and likely to complete the study as planned, as judged by the investigator

Exclusion Criteria:

  • History of any illness or condition that might confound the results of the study or pose an additional risk in administering study drug to the subject
  • Acute respiratory infection, pulmonary exacerbation, or changes in therapy for pulmonary disease within 4 weeks of Day 1 of the study
  • History of alcohol, medication or illicit drug abuse within one year prior to Day 1
  • Abnormal liver function ≥ 3x the upper limit of normal
  • Abnormal renal function at Screening
  • History of solid organ or hematological transplantation
  • Pregnant or breast-feeding (for women)
  • Ongoing participation in another therapeutic clinical study or prior participation in an investigational drug study within 30 days prior to screening
  • Previous participation in a VX-809 study
  • Used inhaled hypertonic saline treatment
  • Concomitant use of any inhibitors or inducers of cytochrome P450 3A4 (CYP3A4)
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00953706

  Show 34 Study Locations
Sponsors and Collaborators
Vertex Pharmaceuticals Incorporated
Cystic Fibrosis Foundation
Investigators
Principal Investigator: Patrick A Flume, MD Medical University of South Carolina
  More Information

Additional Information:
Genetics Home Reference  This link exits the ClinicalTrials.gov site
Medline Plus  This link exits the ClinicalTrials.gov site
U.S. FDA Resources  This link exits the ClinicalTrials.gov site

No publications provided by Vertex Pharmaceuticals Incorporated

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Responsible Party: Vertex Pharmaceuticals Incorporated
ClinicalTrials.gov Identifier: NCT00953706     History of Changes
Other Study ID Numbers: VX08-770-104
Study First Received: August 4, 2009
Results First Received: February 27, 2012
Last Updated: October 25, 2012
Health Authority: United States: Food and Drug Administration

Keywords provided by Vertex Pharmaceuticals Incorporated:
Fibrosis
Pancreatic Diseases
Digestive System Diseases
Lung Diseases
 Respiratory Tract Diseases
Genetic Diseases, Inborn
Infant, Newborn, Diseases
Pathologic Processes

Additional relevant MeSH terms:
Cystic Fibrosis
Fibrosis
Pancreatic Diseases
Digestive System Diseases
Lung Diseases
 Respiratory Tract Diseases
Genetic Diseases, Inborn
Infant, Newborn, Diseases
Pathologic Processes

ClinicalTrials.gov processed this record on June 18, 2013